ZYUS Life Sciences says 3 of 7 evaluable patients met pain threshold

Mugglehead
By Theo MarchettiOct 1, 2026, 8:53 am79 pts
At three Canadian trial sites, Phase 2a cancer-pain results released Oct. 1 showed that three of seven evaluable patients reached a predefined 30 per cent reduction in average pain. ZYUS Life Sciences Corporation (CVE: ZYUS) said its Trichomylin capsules were given to 11 patients in UTOPIA-1 alongside standard…

Read Article Share
Share Article
- email
- x.com
- facebook
- pocket
- reddit
- tumblr
- linkedin
- pinterest

Trending Today on NewsBudz

Bipartisan Congressional Psychedelics Caucus Lays Out Plan For Federal And State Cooperation To Increase Therapeutic Access 78

LFTD Partners' Lifted Made repays bank debt after US$1.5M Kenosha sale 76

ZYUS Life Sciences says 3 of 7 evaluable patients met pain threshold 75

GOP Senators Want Investigation On Chinese Role In U.S. Marijuana And Hemp Industries 71

Georgia Officials Approve New Rule Allowing Medical Marijuana Delivery By USPS, But Federal Agency Won’t Say If It’ll Participate 59

Marijuana and the 2026 Election: What Voters Will Decide on November 3 56

Virginia Cannabis Control Authority Launches Statewide Medical Marijuana Patient Survey to Guide Program Changes 54

Los Angeles Mayoral Candidate Proposes Cutting Marijuana Tax to 0.25%, Launching Cannabis Cafes Before 2028 Olympics 32

About NewsBudz

NewsBudz is your go-to app for daily cannabis news, covering everything from medical marijuana breakthroughs to recreational cannabis trends and legalization updates.

Our platform aggregates content from over 30 top-tier cannabis news outlets to deliver a curated stream of the latest headlines, insights, and developments across the marijuana and hemp industries.

Whether you're interested in policy reform, health research, cannabis business, CBD, delta 9 products or lifestyle stories, NewsBudz keeps you informed and connected. Accessible on the web and mobile, NewsBudz makes it easy to explore, read, and share cannabis news anytime, anywhere.